Retatrutide TRIUMPH-1 (2023) and TRIUMPH-2 (2024) TRIUMPH-1 (Jastreboff et al., NEJM 2023): 338 non-diabetic adults with obesity, 48 weeks at escalating doses: 12 mg dose: 24.2% weight loss 8 mg dose: 22.8% 4 mg dose: 17.5% Placebo: 2.1% TRIUMPH-2 (Rosenstock et al., Lancet 2024) confirmed effects in T2D patients with concurrent NAFLD improvement (hepatic fat reduction 54% at 24 weeks, 12 mg dose)
Body composition analyses using dual-energy X-ray absorptiometry (DEXA) scans revealed that a majority of the weight lost was fat mass
Enter your dose, the vial amount, and the bacteriostatic water you added
In cardiovascular diseases, regular consumption of antioxidant foods, such as extra virgin olive oil, has been associated with a reduction in hepatic steatosis, lipid peroxidation, and vascular inflammation, effects that contribute significantly to endothelial protection and the prevention of atherosclerosis [86, 87]
Skip the soda Instead of a sugary soda, get water, says Young